Combinations of Bevacizumab With Cancer Immunotherapy

Keywords  
Atezolizumab, avelumab, bevacizumab, cancer immunotherapy, cytotoxic
T-lymphocyte antigen 4 (CTLA-4), durvalumab, immuno-oncology, nivolumab,
pembrolizumab, programmed death 1 (PD-1), programmed death ligand 1 (PD-L1),
vascular endothelial growth factor (VEGF)

